TABLE 2.
Pyrazinamide concentrations in plasma, ELF, and AC
| Sample | Valuea for:
|
|||
|---|---|---|---|---|
| Men with AIDS (n = 10) | Men without AIDS (n = 10) | Women with AIDS (n = 10) | Women without AIDS (n = 10) | |
| Plasma | ||||
| 2 h | 20 ± 4.2 | 23.6 ± 7.0 | 28.5 ± 10.3b | 28.2 ± 4.7b |
| 4 h | 16.4 ± 5.42 | 20.1 ± 6.2 | 25.0 ± 7.1c | 23.0 ± 5.8c |
| ELF | ||||
| Mean ± SD | 406 ± 198d | 443 ± 180d | 340 ± 167d | 535 ± 297d |
| Range | 115–674 | 184–752 | 136–577 | 146–1102 |
| AC | ||||
| Mean ± SD | 12.2 ± 10.2d | 21.8 ± 18.6d | 12.2 ± 17.0d | 22.3 ± 21.0d |
| Range | 1.0–32.0 | 3.2–60.0 | 0–53.4 | 3.3–74.6 |
a
Data are given as the mean ± 1 SD in micrograms per milliliter. Range data are given as minimum to maximum in micrograms per milliliter.
b
For women versus men, the P value was 0.005; there was no significant effect of the presence of AIDS alone (P, 0.67) or of the presence of AIDS and gender together (P, 0.15).
c
For women versus men, the P value was 0.005; there was no significant effect of the presence of AIDS alone (P, 0.46) or of the presence of AIDS and gender together (P, 0.39).
d
There was no significant effect of the presence of AIDS or gender alone or of the presence of AIDS and gender together (P, >0.05) on pyrazinamide concentrations in ELF or AC.